Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists

Abstract

Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

1 - 18 . (canceled) 
     
     
         19 . A method for treating schizophrenia in a subject in need thereof, the method comprising administering a therapeutic composition comprising beta-caryophyllene (BCP) and a pharmaceutically effective carrier. 
     
     
         20 . The method of  claim 19 , wherein said schizophrenia is selected from the group consisting of paranoid schizophrenia; disorganized schizophrenia; undifferentiated schizophrenia; catatonic schizophrenia; and residual schizophrenia. 
     
     
         21 . The method of  claim 19 , wherein said treating comprises treating at least one symptom of schizophrenia selected from the group consisting of a negative symptom of schizophrenia and a positive symptom of schizophrenia. 
     
     
         22 . The method of  claim 19 , wherein an average daily amount of said BCP administered is from about 0.4 mg/kg to about 2 mg/kg. 
     
     
         23 . The method of  claim 19 , wherein said pharmaceutically effective carrier comprises dimethyl sulfoxide (DMSO). 
     
     
         24 . The method of  claim 19 , wherein said administering comprises injecting said composition to said subject. 
     
     
         25 . The method of  claim 19 , wherein said administering comprises orally administering said composition to said subject. 
     
     
         26 . The method of  claim 19 , further comprising co-administering at least one additional antipsychotic agent. 
     
     
         27 . The method of  claim 26 , wherein said at least one additional antipsychotic agent is selected from the group consisting of chlorpromazine, haloperidol, perphenazine, fluphenazine, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and paliperidone, or combinations thereof. 
     
     
         28 . The method of  claim 26 , wherein said at least one additional antipsychotic agent is co-administered in a single dosage form together with said BCP. 
     
     
         29 . The method of  claim 26 , wherein said at least one additional antipsychotic agent is co-administered in a dosage form separate from said BCP. 
     
     
         30 - 32 . (canceled)